View in EDS

Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.

Saved in:
Bibliographic Details
Title: Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.
Authors: Papp, Kim A.1,2 kapapp@probitymedical.com, Lebwohl, Mark G.3, Puig, Lluís4, Ohtsuki, Mamitaro5, Beissert, Stefan6, Gooderham, Melinda7,8, Amin, Ahmad Z.9, Wu, Tianshuang10, Rubant, Simone10, Bialik, Brenton10, Ashley, Doug10, Soliman, Ahmed M.10, Chen, Michael M.10, Blauvelt, Andrew11
Source: American Journal of Clinical Dermatology. Sep2025, Vol. 26 Issue 5, p829-841. 13p.
Database: Academic Search Ultimate
Description
ISSN:11750561
DOI:10.1007/s40257-025-00964-6